Clinical Trials

1 studies in Cardiorenal Syndrome

1. Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function Rochester, MN View Summary
   Close

   Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   To advance our understanding of the mechanisms of human cardiorenal syndrome with emphasis upon the interaction of diuretic therapy and the renal-angiotensin-aldosterone -system and cGMP pathway. The belief is that the chronic AT1 receptor blockade in subjects with compensated CHF and renal dysfunction will improve renal function with increased sodium excretion, glomerular filtration rate and effective renal plasma flow and renal function reserve as compared to the response of placebo-treated subjects.

   NCT ID:

   NCT01678794

   IRB Number:

   09-003284

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Lynn Harstad 507-284-4838